Literature DB >> 18032077

Therapeutic effects of exogenous surfactant enriched with dextran in newborn rabbits with respiratory failure induced by airway instillation of albumin.

A Calkovska1, M Some, B Linderholm, T Curstedt, B Robertson.   

Abstract

The aim of the study was to investigate lung function and morphology in newborn rabbits with acute respiratory failure induced by airway instillation of albumin and to test whether the therapeutic effect of exogenous modified natural surfactant could be enhanced by addition of dextran. Rabbits (gestational age 29 days) were ventilated with 100% O2 and tidal volume 8-10 ml/kg. Respiratory failure was induced by tracheal instillation of albumin (50 or 100mg/ml; 2 ml/kg) and the instillation was repeated 15 min later. Surfactant (Curosurf, 200mg/kg) with or without addition of dextran (30 mg/ml) was administered 15 min after the second dose of albumin and animals were then ventilated for another 60 min. In one series of experiments, instillation of albumin was followed by administration of diluted Curosurf (40 mg/kg) with or without dextran (30 mg/ml). Animals with initial lung-thorax compliance (CLT)<0.6 ml/kg cm H2O were directly treated with surfactant without previous instillation of albumin. Animals treated with a larger dose of Curosurf (200mg/kg) showed a significant increase in CLT at 60 min with no difference between groups receiving high or low dose of albumin. Addition of dextran to Curosurf at high dose (200mg/kg) reduced the therapeutic response (P<0.05 vs. Curosurf without dextran). After treatment with low-dose Curosurf (40 mg/kg) CLT increased more prominently after Curosurf+dextran than after non-enriched surfactant (P<0.05). Dextran potentiated the treatment effect of Curosurf at suboptimal dose (40 mg/kg) but not at high dose (200mg/kg) in animals with low-grade surfactant deficiency or respiratory failure induced by airway instillation of albumin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032077     DOI: 10.1016/j.pupt.2007.10.003

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  2 in total

1.  Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.

Authors:  Yuliannis Lugones; Odalys Blanco; Elena López-Rodríguez; Mercedes Echaide; Antonio Cruz; Jesús Pérez-Gil
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

2.  New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs.

Authors:  Matthias Seehase; Jennifer J P Collins; Elke Kuypers; Reint K Jellema; Daan R M G Ophelders; Olga L Ospina; J Perez-Gil; Federico Bianco; Raffaella Garzia; Roberta Razzetti; Boris W Kramer
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.